{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:34:22Z","timestamp":1788870862846,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T00:00:00Z","timestamp":1297296000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["M093011"],"award-info":[{"award-number":["M093011"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      The Philadelphia (Ph) chromosome and\/or Breakpoint cluster region\u2010Abelson leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML). However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cytogenetic and molecular results of CML patients to evaluate their correlation with clinical presentations and outcome. A total of 84 newly diagnosed CML patients were enrolled in the study. Patients were treated according to disease status. Bone marrow samples were obtained to perform cytogenetic and molecular studies. Clinical presentations, treatment courses, and survival were reviewed retrospectively. Among 84 patients, 72 had chronic phase and 12 had accelerated phase CML. Cytogenetic study showed 69 (82.1%) with the classic Ph chromosome, 6 (7.2%) with a variant Ph chromosome, and 9 (10.7%) with additional chromosome abnormalities. Fifty\u2010four (64.3%) cases harbored b3a2 transcripts, 29 (34.5%) had b2a2 transcript, and 1 had e19a2 transcript. There was no difference in clinical presentations between different cytogenetic and molecular groups; however, additional chromosome abnormalities were significantly associated with the accelerated phase. Imatinib therapy was an effective treatment, as measured by cytogenetic response, when administered as first\u2010 and second\u2010line therapy in chronic phase patients. Survival analysis showed that old age, additional chromosome abnormalities, high Sokal score, and no cytogenetic response in second\u2010line therapy had a significant poor impact (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05). In conclusion, we presented the cytogenetic and molecular pattern of CML patients and demonstrated that the additional chromosome abnormality was associated with poor outcome.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.kjms.2010.09.001","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T04:40:03Z","timestamp":1297399203000},"page":"49-54","source":"Crossref","is-referenced-by-count":9,"title":["Additional chromosome abnormalities in chronic myeloid leukemia"],"prefix":"10.1002","volume":"27","author":[{"given":"Hui\u2010Hua","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui\u2010Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui\u2010Feng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao\u2010Sung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Fung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen J.","year":"1984","journal-title":"Cell"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/306277a0"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3343"},{"key":"e_1_2_6_6_2","first-page":"2343","article-title":"The BCR gene and Philadelphia chromosome\u2010positive leukemogenesis","volume":"61","author":"Laurent E.","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206094"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04291.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309047856"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(99)00187-9"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(03)00128-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V78.5.1155.1155","article-title":"Does the breakpoint within the major breakpoint cluster region (M\u2010bcr) influence the duration of the chronic phase in chronic myeloid leukemia?","volume":"78","author":"Mills K.I.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood.V89.10.3889","article-title":"Relationship between BCR\/ABL fusion proteins and leukemia phenotype","volume":"89","author":"Emilia G.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(97)00263-X"},{"key":"e_1_2_6_16_2","first-page":"193","article-title":"Relationship of the BCR gene breakpoint and the type of BCR\/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia","volume":"8","author":"Prejzner W.","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402922"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johannson B.","year":"2002","journal-title":"Acta Haematol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2003.50043"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400013068"},{"key":"e_1_2_6_22_2","first-page":"143","article-title":"Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome\u2010positive chronic myelogenous leukemia treated with interferon\u2010\u03b1: a Cancer and Leukemia Group B study","volume":"25","author":"Farag S.S.","year":"2004","journal-title":"Int J Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4111"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation","volume":"66","author":"Sokal J.E.","year":"1985","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04955.x"},{"key":"e_1_2_6_28_2","first-page":"61","article-title":"Cytogenetic profile of chronic myeloid leukemias","volume":"39","author":"Jacob R.T.","year":"2002","journal-title":"Indian J Cancer"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome","volume":"126","author":"El\u2010Zimaity M.M.","year":"2004","journal-title":"Br J Haematol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02142.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1732"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200403000-00002"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.leu.2403752","article-title":"Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation","volume":"19","author":"Lange T.","year":"2005","journal-title":"Leukemia"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0140-6736(03)13145-5","article-title":"Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?","volume":"361","author":"Sausville E.A.","year":"2003","journal-title":"Lancet"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X10000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X10000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2010.09.001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.kjms.2010.09.001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2010.09.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:15:51Z","timestamp":1694697351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.kjms.2010.09.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1016\/j.kjms.2010.09.001"],"URL":"https:\/\/doi.org\/10.1016\/j.kjms.2010.09.001","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"value":"1607-551X","type":"print"},{"value":"2410-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}